Feasibility of administering zoledronic acid in palliative patients being cared for in the community: Results of a pilot study

Current Oncology

Volumn 17, Issue 2, 2010, Pages 69-74

  Marr, H K ^a,b   Stiles, C R ^b   Boyar, M A ^b   Braun, T C ^a,b   Hagen, N A ^a,b   Janzen, C ^b   Whitten, L M ^b   Pereira, J L ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bisphosphonates; Bone pain; Home care; Hospice care; Hypercalcemia; Palliative care

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE PAIN; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DELIRIUM; DISEASE ASSOCIATION; DRUG COST; DRUG INFUSION; DYSPNEA; EDEMA; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; GAIT DISORDER; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; MALIGNANT BONE PAIN; METASTATIC BONE PAIN; MULTICENTER STUDY; NURSING COST; PATIENT TRANSPORT; TERMINALLY ILL PATIENT; UNSTEADINESS; WEAKNESS;

EID: 77950584647     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i2.507     Document Type: Article

References (14)

1. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease [executive summary section]. Health Technol Assess 2004;8:1-6.
2. Cascinu S, Casadei V, Del Ferro E, Alessandroni P, Catalano G. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Support Care Cancer 1996;4:31-3.
3. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002;(2):CD002068.
4. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997;13:319-26.
5. Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 2004;64:1197-211.
6. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997;8:915-16.
7. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-67.
8. Italiano A, Ciais C, Chamorey E, et al. Home infusions of biphosphonate in cancer patients: a prospective study. J Chemother 2006;18:217-20.
9. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92:1869-76.
10. Tassinari D, Poggi B, Nicoletti S, et al. Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 2007;10:352-8.
11. Santangelo A, Testai M, Barbagallo P, et al. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 2006;43:187-92.
12. Brooke P, Bullock R. Validation of a 6 item cognitive impairment test with a view to primary care usage. Int J Geriatr Psychiatry 1999;14:936-40.
13. Chern B, Joseph D, Joshua D, et al. Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 2004;12:463-6.
14. Barrett-Lee P, Bloomfield D, Dougherty L, et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin 2007;23:1575-82.